MA
SCNI

Mutual Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

Mutual Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-72
Closed -$280K – 759
2020
Q3 		$280K Buy
+72
New +$276K 0.02% 556

Other funds holding SCNI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Mutual Advisors's SCNI Position: Q4 2020 in Review

Mutual Advisors sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 72 shares — an estimated $280K sold.

Mutual Advisors first reported a position in SCNI in Q3 2020 and held it in 1 quarter. The position peaked at $280K in Q3 2020. 13 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

  • Mutual Advisors reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Mutual Advisors sold 72 Scinai Immunotherapeutics shares in Q4 2020, an estimated $280K.
  • Mutual Advisors first reported a position in Scinai Immunotherapeutics in Q3 2020 and held it in 1 quarter.
  • Mutual Advisors's Scinai Immunotherapeutics position peaked at $280K in Q3 2020.
  • 13 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Mutual Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.